Pulmonx Co. (NASDAQ:LUNG) Director Purchases $71,362.26 in Stock

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) Director Daniel P. Florin purchased 23,321 shares of the business's stock in a transaction on Thursday, June 5th. The stock was purchased at an average cost of $3.06 per share, with a total value of $71,362.26. Following the acquisition, the director now owns 117,231 shares in the company, valued at approximately $358,726.86. This represents a 24.83% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Pulmonx Stock Down 3.6%

Pulmonx stock traded down $0.11 during mid-day trading on Thursday, reaching $2.97. The stock had a trading volume of 302,125 shares, compared to its average volume of 312,372. The firm has a market capitalization of $119.57 million, a PE ratio of -2.06 and a beta of 0.52. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. Pulmonx Co. has a fifty-two week low of $2.83 and a fifty-two week high of $9.37. The stock's 50-day simple moving average is $4.34 and its 200-day simple moving average is $5.97.

Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.01. The business had revenue of $22.54 million for the quarter, compared to analysts' expectations of $22.03 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, sell-side analysts forecast that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LUNG shares. Citigroup cut their target price on shares of Pulmonx from $6.50 to $4.15 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Morgan Stanley started coverage on Pulmonx in a research report on Monday, March 10th. They issued an "equal weight" rating for the company. Canaccord Genuity Group dropped their price objective on Pulmonx from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Jefferies Financial Group started coverage on Pulmonx in a research note on Monday, March 10th. They set a "buy" rating on the stock. Finally, D. Boral Capital restated a "buy" rating and issued a $17.00 price target on shares of Pulmonx in a research note on Thursday, May 1st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $11.53.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC grew its holdings in shares of Pulmonx by 27.0% in the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock worth $106,000 after purchasing an additional 3,310 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Pulmonx by 4.9% during the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company's stock valued at $363,000 after purchasing an additional 2,488 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Pulmonx by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company's stock valued at $2,142,000 after purchasing an additional 2,363 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Pulmonx by 44.8% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,941 shares of the company's stock valued at $570,000 after buying an additional 25,988 shares during the period. Finally, American Century Companies Inc. grew its position in Pulmonx by 8.8% during the fourth quarter. American Century Companies Inc. now owns 34,738 shares of the company's stock valued at $236,000 after buying an additional 2,810 shares during the period. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.